Association of TNF and FcγRIIA gene polymorphisms with differential response to infliximab in a Greek cohort of crohn's disease patients

Annals of Gastroenterology

Volumn 24, Issue 1, 2011, Pages 35-40

  Papamichaela, Konstantinos ^a   Gazoulib, Maria ^b   Karakoidasa, Christos ^a   Panayotouc, Ioanna ^b   Roma Giannikouc, Eleftheria ^b   Mantzarisa, Gerassimos J ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Crohn's disease; Fc RIIA polymorphisms; Infliximab; Promoter TNF gene

Indexed keywords

ADENINE; CYTOSINE; DNA; FC RECEPTOR IIA; GUANOSINE; INFLIXIMAB; THYMIDINE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CHILD; CROHN DISEASE; DNA POLYMORPHISM; FEMALE; GENOTYPE; GREECE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 79952013348     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
3. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
4. González-Lama Y, López-San Román A, Marín-Jiménez I, et al. Group for the Study of Inflammatory Bowel Diseases from Madrid (ENICMAD). Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. Gastroenterol Hepatol 2008; 31: 421-226.
5. Teshima CW, Thompson A, Dhanoa L, Dieleman LA, Fedorak RN. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009; 23: 348-352.
6. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135: 1114-1122.
7. Hyams J, Crandall W, Kugathasan S, et al. REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-873.
8. Mascheretti S, Schreiber S. The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease. Pharmacogenomics 2004; 5: 479-486.
9. Pierik M, Vermeire S, Steen KV, et al. Tumour necrosis factoralpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004; 20: 303-310.
10. Mascheretti S, Hampe J, Kühbacher T, et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002; 2: 127-136.
11. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 818-824.
12. Dubinsky MC, Mei L, Friedman M, et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. In flamm Bowel Dis 2010 [In press].
13. Dideberg V, Théâtre E, Farnir F, et al. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet Genomics 2006; 16: 727-734.
14. Ozeki T, Furuya Y, Nagano C, et al. Analysis of linkage between lymphotoxin alpha haplotype and polymorphisms in 5'-flanking region of tumor necrosis factor alpha gene associated with efficacy of infliximab for Crohn's disease patients. Mutat Res 2006; 602: 170-174.
15. Balog A, Klausz G, Gál J, et al. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNFalpha production and apoptosis. Pathobiology 2004; 71: 274-280.
16. De Haas M. IgG-Fc receptors and the clinical relevance of their polymorphisms. Wien Klin Wochenschr 2001; 113: 825-831.
17. Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and with biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004; 19: 511-519.
18. Louis EJ, Watier HE, Schreiber S, et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 2006; 16: 911-914.
19. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J of Gastroenter 1989; 170: 2-6.
20. Harvey and Bradshaw: Lancet 1980; 1: 514.
21. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50: 667-671.
22. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009; 15: 375-382.
23. Fargion S, Valenti L, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 2001; 97: 3707-3712.
24. Seyhan EC, Cetinkaya E, Altin S, et al. Tumor necrosis factor gene polymorphisms in Turkish patients with sarcoidosis. Intern Med 2008; 47: 833-838.
25. Leppers-van de Straat FG, van der Pol WL, Jansen MD, et al. A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. J Immunol Methods 2000; 242: 127-132.
26. Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 2007; 13: 1100-1105.
27. Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395.
28. Tomita K, Chiba T, Sugai T, et al. Association between tumor necrosis factor-alpha and Fc-gamma receptor polymorphisms with infliximab in Crohn's disease. Hepatogastroenterol 2010; 57: 535-539.
29. Shetty A, Forbes A. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease. Am J Pharmacogenomics 2002; 2: 215-221.